- Home
- PRG vs VERV Comparison
PRG vs VERV Comparison
Compare PRG & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- VERV
- Stock Information
- Founded
- PRG 2020
- VERV 2018
- Country
- PRG United States
- VERV United States
- Employees
- PRG N/A
- VERV N/A
- Industry
- PRG Diversified Commercial Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- PRG Consumer Discretionary
- VERV Health Care
- Exchange
- PRG Nasdaq
- VERV Nasdaq
- Market Cap
- PRG 1.1B
- VERV 1.0B
- IPO Year
- PRG N/A
- VERV 2021
- Fundamental
- Price
- PRG $30.18
- VERV $11.06
- Analyst Decision
- PRG Strong Buy
- VERV Buy
- Analyst Count
- PRG 5
- VERV 11
- Target Price
- PRG $41.80
- VERV $14.57
- AVG Volume (30 Days)
- PRG 375.2K
- VERV 7.6M
- Earning Date
- PRG 07-23-2025
- VERV 08-07-2025
- Dividend Yield
- PRG 1.73%
- VERV N/A
- EPS Growth
- PRG 99.08
- VERV N/A
- EPS
- PRG 4.90
- VERV N/A
- Revenue
- PRG $2,505,714,000.00
- VERV $59,613,000.00
- Revenue This Year
- PRG $1.36
- VERV $47.32
- Revenue Next Year
- PRG $4.29
- VERV N/A
- P/E Ratio
- PRG $6.14
- VERV N/A
- Revenue Growth
- PRG 4.62
- VERV 271.44
- 52 Week Low
- PRG $23.50
- VERV $2.87
- 52 Week High
- PRG $50.28
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- PRG 56.16
- VERV 78.23
- Support Level
- PRG $29.85
- VERV $11.16
- Resistance Level
- PRG $30.83
- VERV $11.30
- Average True Range (ATR)
- PRG 0.79
- VERV 0.12
- MACD
- PRG 0.06
- VERV -0.18
- Stochastic Oscillator
- PRG 75.82
- VERV 12.50
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.